Technical Data
AGR2 (Anterior Gradient 2 Homolog (Xenopus laevis), AG2, GOB-4, HAG-2, XAG-2, Secreted Cement Gland Homolog)
The anterior gradient protein-2 (AGR2) is a cancer cell marker specifically up-regulated in response to depletion of serum and oxygen. It has been identified as a tumor marker in primary and secondary cancer lesions, and as a marker for detection of circulating tumor cells. Elevated levels of AGR2 are known to increase the metastatic potential of cancer cells (1). Specifically, AGR2 may serve as a useful molecular marker and/or potential therapeutic target for hormone-responsive breast tumors (2). AGR2 expression promotes tumor growth in esophageal adenocarcinoma cells as well. Expression was detected in proliferating and differentiated intestinal cells of secretory lineage, suggesting that AGR2 may be important for the growth and development of the intestine as well as esophageal adenocarcinomas (3).

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:128,000
Western Blot: 0.01 g/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
PabIgGAffinity Purified
100ug-20CBlue IceHumanGoat
As reported
Synthetic peptide corresponding to human AGR2.
Purified by immunoaffinity chromatography.
Supplied as a liquid in 0.5 mg/ml tris-saline, 0.02% sodium azide, pH7.3, 0.5% BSA.
Recognizes human AGR2 at ~17-18kD in Human Colon, Duodenum and Lung lysates (calculated MW of 20.0kD according to NP_006399.1). Species Crossreactivity: Canine and mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Zweitzig DR, et al. Mol Cell Biochem. 306(1-2) :255-60, 2007. 2. Fletcher GC, et al. Br J Cancer 88(4): 579-85, 2003. 3. Wang Z, et al. Cancer Res. 68(2): 492-7, 2008 4. Innes HE, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer. 2006 Apr 10;94(7):1057-65.